Publications by authors named "Scott Delach"

Claim this Profile
I
Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.
Ralph Tiedt, Frederick J King, Christelle Stamm, Matthew J Niederst, Scott Delach

Cell Rep· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
Kelli-Ann Monaco, Scott Delach, Jing Yuan, Yuji Mishina, Paul Fordjour

Clin Cancer Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.
Chen Liu, Hengyu Lu, Hongyun Wang, Alice Loo, Xiamei Zhang, Scott Delach

Clin Cancer Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.
Sunkyu Kim, Ralph Tiedt, Alice Loo, Thomas Horn, Scott Delach

Oncotarget· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.
Sunkyu Kim, Ralph Tiedt, Alice Loo, Thomas Horn, Scott Delach

Oncotarget· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
Caroline M Emery, Kelli-Ann Monaco, Ping Wang, Marissa Balak, Alyson Freeman, Scott M Delach

Mol Cancer Res· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma.
Lori S Hart, JulieAnn Rader, Pichai Raman, Vandana Batra, Mike R Russell, Scott Delach

Clin Cancer Res· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Involvement of cathepsin D in chemotherapy-induced cytochrome c release, caspase activation, and cell death.
Lori Emert-Sedlak, Sanjeev Shangary, Asaf Rabinovitz, Michelle B Miranda, Scott M Delach

Mol Cancer Ther· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Whole genome amplification of DNA from laser capture-microdissected tissue for high-throughput single nucleotide polymorphism and short tandem repeat genotyping.
Martha S Rook, Scott M Delach, Galina Deyneko, Andrew Worlock, Jia Liu Wolfe

Am J Pathol· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis